Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus platinum/5-FU vs platinum/5-FU in recurrent/metastatic SCCHN (China)
CTR20150241Phase 3Active
- Sponsor
- Merck KGaA
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Merck KGaA. Started May 2015; status: active.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20150241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150241.